<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1213">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145361</url>
  </required_header>
  <id_info>
    <org_study_id>B001-103</org_study_id>
    <nct_id>NCT05145361</nct_id>
  </id_info>
  <brief_title>Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)</brief_title>
  <official_title>A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of B001 in Subjects With Aquaporin-4 Antibody (AQP4-IgG) Positive Neuromyelitis Optic Spectrum Disorder (NMOSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics,&#xD;
      pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody&#xD;
      (AQP4-IgG) positive NMOSD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to 18 days.</time_frame>
    <description>Measurement of DLT in all subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 18 days.</time_frame>
    <description>Measurement of MTD in all subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability].</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum serum concentration (Tmax) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-14D) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-Last) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of the Dosing Interval (0-infinity) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of maximum serum concentration (Rac_Cmax) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of area under the serum concentration-time curve (Rac_AUC) of the Dosing Interval (0-14D) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant(λz) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance(CL) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution(Vz) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of area under the serum concentration-time curve (AUC 0-infinity) obtained by extrapolation (%AUCex) of B001.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>To characterize the PK (Pharmacokinetics) of B001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with ADA to B001 and neutralizing resistance (Nab)</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Expanded Disability Status Scale (EDSS) Score</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to EDSS Worsening</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>NMO Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>B001 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B001 injection</intervention_name>
    <description>B001 injection 50mg/5mL Intravenous solution</description>
    <arm_group_label>B001 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 5mL Intravenous solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibody (Ab)&#xD;
             seropositive status at screening&#xD;
&#xD;
          2. Clinical evidence of at least 1 documented relapse in last 12 months prior to&#xD;
             screening&#xD;
&#xD;
          3. Expanded Disability Status Scale (EDSS) score from 0 to 7.5 inclusive at screening&#xD;
&#xD;
          4. Age 18 to 70 years, inclusive at the time of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody&#xD;
             (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS)&#xD;
             relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide&#xD;
             or dimethyl fumarate) within 6 months prior to baseline.&#xD;
&#xD;
          2. Received immunosuppression such as azathioprine, mycophenolate mofetil, methotrexate,&#xD;
             cyclophosphamide, tacrolimus, mitoxantrone, cyclosporine A, etc, and rug therapy,&#xD;
             biological agents such as satralizumab, tocilizumab, eculizumab, etc, 3 months prior&#xD;
             to the first administration.&#xD;
&#xD;
          3. Evidence of serious uncontrolled concomitant diseases that may preclude participant&#xD;
             participation, as described; Other nervous system disease, cardiovascular disease,&#xD;
             hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine&#xD;
             disease, renal/urologic disease, digestive system disease, congenital or acquired&#xD;
             severe immunodeficiency.&#xD;
&#xD;
          4. Known active infection within 3 months prior to baseline&#xD;
&#xD;
          5. Pregnancy or lactation.&#xD;
&#xD;
          6. History of severe allergic reaction to a biologic agent&#xD;
&#xD;
          7. Evidence of chronic active hepatitis B or C&#xD;
&#xD;
          8. Evidence of active tuberculosis&#xD;
&#xD;
          9. Following laboratory abnormalities at screening*:&#xD;
&#xD;
               1. White blood cells (WBC) &lt;4.0 x10^3/microliter (μL)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) &lt;2.0 x10^3/μL&#xD;
&#xD;
               3. Absolute lymphocyte count &lt;0.5 x10^3/μL&#xD;
&#xD;
               4. Platelet count &lt;80 x 10^9/ L&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
&#xD;
         10. History of drug or alcohol abuse within 6 months prior to baseline&#xD;
&#xD;
         11. Receipt of any live or live attenuated vaccine within 4 weeks prior to baseline&#xD;
&#xD;
         12. Uncontrolled systemic diseases, including hypertension that cannot be effectively&#xD;
             controlled after treatment (systolic blood pressure ≥150 mmHg and/or diastolic blood&#xD;
             pressure ≥100 mmHg), diabetes, gastrointestinal diseases, etc.; or the investigator&#xD;
             believes that there is anything inappropriate reasons for selection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Dong Shi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu-Dong Shi, MD,PhD</last_name>
    <phone>022-60814587</phone>
    <email>Shifudong219@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chao Zhang, MD</last_name>
      <phone>022-60814587</phone>
      <email>chaozhang@tmu.edu.can</email>
    </contact>
    <investigator>
      <last_name>Fu-Dong Shi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

